Evogene replaces two directors with Pure Capital nominees under cooperation deal

• Evogene struck a cooperation deal with Pure Capital Group, setting a board reconstitution to end a shareholder dispute.
• Directors Yael Margolin and Yoshinori Oikawa resigned; Pure Capital nominees Adi Zuluf-Shani and Oz Adler were named as replacements.
• A shareholder vote is slated within 42 days to elect Zuluf-Shani and Adler, conditional on approval of the cooperation agreement.
• The same meeting would also vote on seating Itay Maroz and Shahar Zadok, replacing Dan Falk and Adrian Percy.
• If approved, the board would have seven directors, including four Pure Capital nominees, with a transition period expected to last up to six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN64970) on October 06, 2026, and is solely responsible for the information contained therein.